NAUT.US Nautilus Biotechnology Inc

Healthcare Biotechnology USA Stocks
2.32 USD
Close of Nov 15, 2026
0.8410 4.31
Market cap
USD 296M
P/E
-
P/B
2.53x
ROE
-51.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NAUT.US undervalued?

Graham number

The Graham number of Nautilus Biotechnology Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nautilus Biotechnology Inc fundamental analysis

No fundamental analysis for Nautilus Biotechnology Inc yet.

Nautilus Biotechnology Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nautilus Biotechnology Inc

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid ha…

Full company profile